查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496163

全球神经内分泌肿瘤 (NET) 市场（2024 年版）：按治疗、给药途径、适应症、最终用户和区域、市场考虑因素和预测进行分析（2020-2030 年）

Global Neuroendocrine Tumors (NETs) Market (2024 Edition): Analysis By Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), By Route of Administration, By Indication, By End User, By Region: Market Insights and Forecast (2020-2030)
出版日期: | 出版商: Azoth Analytics | 英文 300 Pages | 订单完成后即时交付

价格

2020-2023年全球神经内分泌肿瘤（NET）市场规模复合年增长率为8.98%。 2023年市场规模为35.7亿美元，预计2030年将达69.4亿美元。由于 NET 的发病率和盛行率增加、医疗保健成本上升、老年人口增加、医疗保健基础设施改善以及宣传活动和患者支持活动不断增加，该市场正在呈现显着增长。

近年来，全球 NET 的发生率和盛行率显着增加。多种因素促成了这一趋势，包括诊断技术的改进导致检出率更高、医疗保健专业人员的意识提高以及人口老化。随着越来越多的病例被诊断出来，对 NET 患者的诊断测试、治疗方案和支持性护理服务的需求不断增加。

此外，随着标靶治疗药物和新治疗方法的出现，NET的治疗正在发生重大变化。生长抑制素类似物如Octreotide和Lanreotide可控制荷尔蒙症状并抑制某些 NET 亚型的肿瘤生长。 PRRT 对錶达生长抑制素受体的癌细胞进行标靶放射治疗，为晚期疾病患者提供了一种有前途的治疗选择。此外，正在进行的免疫疗法、联合治疗和基于基因的方法的研究有可能进一步扩大 NET 的治疗方法，推动市场成长。

精准医学和分子诊断的进步使得针对个别肿瘤分子特征的个人化治疗策略成为可能。生物标记主导的方法根据特定的肿瘤标记、生长抑制素受体表达模式和基因变化来识别最有可能从 SSA 治疗中受益的患者。这允许更有针对性和更有效的治疗选择，优化治疗结果，同时最大限度地减少不必要的药物暴露。

奈米技术的进步也促进了用于 NET 治疗胃肠外给药的微球和奈米颗粒製剂的开发。这些製剂将药物封装在生物分解性的聚合物基质或脂质奈米颗粒中，从而可以控制释放并靶向递送至肿瘤组织。微球和奈米颗粒製剂具有提高药物稳定性、增强肿瘤渗透性和延长体内循环时间等优点。透过优化药物药物动力学和生物分布，这些製剂可改善治疗结果，同时最大限度地减少脱靶效应。

正在进行的研究正在调查用于胃肠道 NET局部药物传输和影像引导治疗的靶向内视镜输送系统。药物释放型支架、显微注射器和磁导航系统等新型内视镜平台能够将治疗药物直接精确地输送到肿瘤部位。这些标靶递送系统可以提高化疗、免疫疗法和胜肽受体放射性核素疗法（PRRT）等治疗方法的疗效和安全性，同时最大限度地减少全身暴露和脱靶效应。即时成像和导航功能能够精确定位和监测治疗反应，优化治疗结果，同时最大限度地减少手术併发症。

该报告审视了全球神经内分泌肿瘤 (NET) 市场，并提供了包括市场规模和预测、区域和細項分析以及主要趋势和机会在内的资讯。

目录

第一章 市集背景

  • 产品范围和产品前景
  • 执行摘要
  • 调查方法

第二章 战略建议

  • 设立专门治疗中心
  • 意识提升宣传活动的管理

第三章全球神经内分泌肿瘤（NET）市场：表现与预测

  • 宏观经济因素对全球神经内分泌肿瘤（NET）市场的影响分析
  • 管道场景
  • 流行病学：全球 NET 盛行率
  • 流行病学：全球 NET 盛行率
  • 全球神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
  • COVID-19 对神经内分泌肿瘤 (NET) 市场的影响
  • 全球神经内分泌肿瘤 (NET) 市场细分：按治疗方法
    • 全球神经内分泌肿瘤 (NET) 市场：依治疗方法、概述
    • 全球神经内分泌肿瘤 (NET) 市场吸引力指数：依治疗方法、概述
    • 全球神经内分泌肿瘤（NET）市场规模：生长抑制素类似物（SSA）（金额）（2020-2030）
    • 全球神经内分泌肿瘤（NET）市场规模：标靶治疗（金额）（2020-2030）
    • 全球神经内分泌肿瘤（NET）市场规模：其他（金额）（2020-2030）
  • 全球神经内分泌肿瘤 (NET) 市场细分：按给药途径
    • 全球神经内分泌肿瘤 (NET) 市场：依给药途径、概述
    • 全球神经内分泌肿瘤 (NET) 市场吸引力指数：按给药途径，概述
    • 全球神经内分泌肿瘤（NET）市场规模：口服（金额）（2020-2030）
    • 全球神经内分泌肿瘤（NET）市场规模：肠外（金额）（2020-2030）
  • 全球神经内分泌肿瘤 (NET) 市场细分：按适应症
    • 全球神经内分泌肿瘤 (NET) 市场：按适应症、概述
    • 全球神经内分泌肿瘤 (NET) 市场吸引力指数：按适应症、概述
    • 全球神经内分泌肿瘤（NET）市场规模：肺内分泌肿瘤（金额）（2020-2030）
    • 全球神经内分泌肿瘤（NET）市场规模：胰臟内分泌肿瘤（金额）（2020-2030）
    • 全球神经内分泌肿瘤（NET）市场规模：胃肠道内分泌肿瘤（金额）（2020-2030）
    • 全球神经内分泌肿瘤（NET）市场规模：其他（金额）（2020-2030）
  • 全球神经内分泌肿瘤 (NET) 市场细分：按最终用户
    • 全球神经内分泌肿瘤 (NET) 市场：按最终用户划分，概述
    • 全球神经内分泌肿瘤 (NET) 市场吸引力指数：按最终用户划分，概述
    • 全球神经内分泌肿瘤（NET）市场规模：医院（金额）（2020-2030）
    • 全球神经内分泌肿瘤（NET）市场规模：专科诊所（金额）（2020-2030）
    • 全球神经内分泌肿瘤（NET）市场规模：放射线中心（金额）（2020-2030）

第四章全球神经内分泌肿瘤（NET）市场，区域分析

  • 研究的区域范围
  • 区域简介

第五章美洲神经内分泌肿瘤（NET）市场：表现与预测

  • 美洲神经内分泌肿瘤 (NET) 市场：概述
  • 美洲神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
  • 美洲神经内分泌肿瘤 (NET) 市场：主要驱动因素
  • 美洲神经内分泌肿瘤（NET）市场：細項分析
  • 美洲神经内分泌肿瘤 (NET) 市场细分：按治疗方法
  • 按给药途径分類的美洲神经内分泌肿瘤 (NET) 市场细分
  • 美洲神经内分泌肿瘤 (NET) 市场细分：按适应症
  • 美洲神经内分泌肿瘤 (NET) 市场细分：按最终用户
  • 按国家/地区分類的美洲神经内分泌肿瘤 (NET) 市场细分
    • 欧洲神经内分泌肿瘤 (NET) 市场：按国家/地区划分，概述
    • 美国神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
    • 加拿大神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
    • 其他美洲神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）

第六章欧洲神经内分泌肿瘤（NET）市场：表现与预测

  • 欧洲神经内分泌肿瘤 (NET) 市场：概述
  • 欧洲神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
  • 欧洲神经内分泌肿瘤（NET）市场：主要驱动因素
  • 欧洲神经内分泌肿瘤（NET）市场：細項分析
  • 欧洲神经内分泌肿瘤 (NET) 市场细分：按治疗方法
  • 欧洲神经内分泌肿瘤 (NET) 市场细分：按给药途径
  • 欧洲神经内分泌肿瘤 (NET) 市场细分：按适应症
  • 欧洲神经内分泌肿瘤 (NET) 市场细分：按最终用户
  • 欧洲神经内分泌肿瘤 (NET) 市场细分：按国家/地区
    • 欧洲神经内分泌肿瘤 (NET) 市场：按国家/地区划分，概述
    • 英国神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
    • 德国神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
    • 法国神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
    • 西班牙神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
    • 其他欧洲神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）

第七章亚太神经内分泌肿瘤（NET）市场：表现与预测

  • 亚太地区神经内分泌肿瘤 (NET) 市场：概述
  • 亚太地区神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
  • 亚太地区神经内分泌肿瘤（NET）市场：主要驱动因素
  • 亚太地区神经内分泌肿瘤（NET）市场：細項分析
  • 亚太地区神经内分泌肿瘤 (NET) 市场区隔：按治疗方法
  • 按给药途径分類的亚太地区神经内分泌肿瘤 (NET) 市场细分
  • 亚太地区神经内分泌肿瘤 (NET) 市场区隔：按适应症
  • 亚太地区神经内分泌肿瘤 (NET) 市场细分：按最终用户
  • 亚太地区神经内分泌肿瘤 (NET) 市场细分：按国家/地区
    • 亚太地区神经内分泌肿瘤 (NET) 市场：按国家/地区划分，概述
    • 中国神经内分泌肿瘤（NET）市场：市场规模及复合年增长率（2020-2030）
    • 日本神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
    • 印度神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
    • 韩国神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
    • 其他亚太地区神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）

第 8 章中东和非洲神经内分泌肿瘤 (NET) 市场：表现与预测

  • 中东和非洲神经内分泌肿瘤 (NET) 市场：概述
  • 中东和非洲神经内分泌肿瘤（NET）市场：市场规模和复合年增长率（2020-2030）
  • 中东和非洲神经内分泌肿瘤 (NET) 市场：主要驱动因素
  • 中东和非洲神经内分泌肿瘤 (NET) 市场：細項分析
  • 中东和非洲神经内分泌肿瘤 (NET) 市场细分：按治疗方法
  • 中东和非洲神经内分泌肿瘤 (NET) 市场按给药途径细分
  • 中东和非洲神经内分泌肿瘤 (NET) 市场细分：按适应症
  • 中东和非洲神经内分泌肿瘤 (NET) 市场细分：按最终用户

第九章市场动态

  • 评估市场动态对全球神经内分泌肿瘤（NET）市场的影响
  • 促进因素
  • 抑制因素
  • 趋势

第10章产业生态系分析

  • 波特分析

第十一章竞争定位

  • 企业产品定位
  • 主要企业市场占有率
  • 公司简介
    • Novartis
    • Pfizer
    • Amgen, Inc.
    • GlaxoSmithKline
    • F. Hoffmann-La Roche AG
    • Bristol-Myers Squibb Co.
    • Eli Lilly and Company
    • Ipsen
    • Lantheus Holdings
    • Boehringer Ingelheim

第十二章 关于我们公司、免责声明

Executive Summary

Azoth Analytics has released a research report titled "Global Neuroendocrine Tumors (NETs) Market (2024 Edition)" which provides a complete analysis of the Global Neuroendocrine Tumors (NETs) industry in terms of market segmentation by Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), by Route of Administration (Oral, Parenteral), by Indication (Lung Endocrine Tumor, Pancreatic Endocrine Tumor, Gastrointestinal Endocrine Tumor, Others), by End User (Hospitals, Specialty Clinics, Radiation Centers) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.

The report analyses the Neuroendocrine Tumors (NETs) Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, India, Japan, South Korea). The Global Neuroendocrine Tumors (NETs) market showcased growth at a CAGR of 8.98% during 2020-2023. The market was valued at USD 3.57 Billion in 2023 which is expected to reach USD 6.94 Billion in 2030. The market for Neuroendocrine Tumors (NETs) has seen significant growth due to the increasing incidence and prevalence of NETs, rising healthcare expenditure, a growing geriatric population, improvements in healthcare infrastructure, and heightened awareness campaigns and patient advocacy efforts.

Over recent years, there has been a notable rise in the incidence and prevalence of NETs globally. Several factors contribute to this trend, including improved diagnostic techniques leading to better detection rates, heightened awareness among healthcare professionals, and an aging population. As more cases are diagnosed, the demand for diagnostic tests, treatment options, and supportive care services for NET patients continues to grow.

Furthermore, the emergence of targeted therapies and novel treatment modalities has transformed the management of NETs. Somatostatin analogs, such as octreotide and lanreotide, control hormonal symptoms and inhibit tumor growth in certain subtypes of NETs. PRRT delivers targeted radiation to tumor cells expressing somatostatin receptors, offering a promising therapeutic option for patients with advanced disease. Furthermore, ongoing research into immunotherapies, combination therapies, and gene-based approaches holds potential for further expanding the treatment armamentarium for NETs, driving market growth.

Advancement in precision medicine and molecular diagnostics enable personalized treatment strategies tailored to the molecular characteristics of individual tumors. Biomarker-driven approaches identify patients who are most likely to benefit from SSA therapy based on specific tumor markers, somatostatin receptor expression patterns, and genetic alterations. This allows for more targeted and effective treatment selection, optimizing therapeutic outcomes while minimizing unnecessary exposure to medications.

Also, advancement in nanotechnology enable the development of microsphere and nanoparticle formulations for parenteral administration of NETs therapies. These formulations encapsulate the drug within biodegradable polymer matrices or lipid-based nanoparticles, allowing for controlled release and targeted delivery to tumor tissues. Microsphere and nanoparticle formulations offer advantages such as improved drug stability, enhanced tumor penetration, and prolonged circulation time in the body. By optimizing drug pharmacokinetics and biodistribution, these formulations enhance treatment outcomes while minimizing off-target effects.

Ongoing research explores targeted endoscopic delivery systems for localized drug delivery and image-guided therapy in gastrointestinal NETs. Novel endoscopic platforms, such as drug-eluting stents, micro-injectors, and magnetic navigation systems, enable precise delivery of therapeutic agents directly to the tumor site. These targeted delivery systems enhance the efficacy and safety of treatment modalities, such as chemotherapy, immunotherapy, and peptide receptor radionuclide therapy (PRRT), by minimizing systemic exposure and off-target effects. Real-time imaging and navigation capabilities allow for precise localization and monitoring of therapeutic response, optimizing treatment outcomes while minimizing procedural complications.

Scope of the Report:

  • The report analyses the Neuroendocrine Tumors (NETs) Market by Value (USD Million).
  • The report analyses the Neuroendocrine Tumors (NETs) Market by Pipeline Scenario.
  • The report analyses the Neuroendocrine Tumors (NETs) Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, India, Japan, South Korea).
  • The report analyses the Neuroendocrine Tumors (NETs) Market by Epidemiology.
  • The report presents the analysis of Neuroendocrine Tumors (NETs) Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
  • The report analyses the Neuroendocrine Tumors (NETs) Market by Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others).
  • The report analyses the Neuroendocrine Tumors (NETs) Market by Route of Administration (Oral, Parenteral).
  • The report analyses the Neuroendocrine Tumors (NETs) Market by Indication (Lung Endocrine Tumor, Pancreatic Endocrine Tumor, Gastrointestinal Endocrine Tumor, Others).
  • The report analyses the Neuroendocrine Tumors (NETs) Market by End User (Hospitals, Specialty Clinics, Radiation Centers).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by source, by application, by indication, & by end user.
  • Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis, Pfizer, Amgen, Inc., GlaxoSmithKline, F. Hoffmann-La Roche AG, Bristol-Myers Squibb Co., Eli Lilly and Company, Ipsen, Lantheus Holdings, and Boehringer Ingelheim.

Table of Contents

1. Market Background

  • 1.1 Scope and Product Outlook
  • 1.2 Executive Summary
  • 1.3 Research Methodology

2. Strategic Recommendations

  • 2.1 Establishment of specialist therapeutic centers
  • 2.2 Organize campaigns to raise awareness

3. Global Neuroendocrine Tumors (NETs) Market: Historic and Forecast

  • 3.1 Impact Analysis of Macro Economic Factors on Global Neuroendocrine Tumors (NETs) Market
  • 3.2 Pipeline Scenario
  • 3.3 Epidemiology: Global NETs Prevalence
  • 3.4 Epidemiology: Global NETs Incidence
  • 3.5 Global Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 3.6 Degree of Impact of Covid-19 on Neuroendocrine Tumors (NETs) Market
  • 3.7 Global Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
    • 3.7.1 Global Neuroendocrine Tumors (NETs) Market, By Therapy Overview
    • 3.7.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By Therapy Overview
    • 3.7.3 Global Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
    • 3.7.4 Global Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.7.5 Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.8 Global Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
    • 3.8.1 Global Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
    • 3.8.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By Route of Administration Overview
    • 3.8.3 Global Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.8.4 Global Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.9 Global Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
    • 3.9.1 Global Neuroendocrine Tumors (NETs) Market, By Indication Overview
    • 3.9.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By Indication Overview
    • 3.9.3 Global Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.9.4 Global Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.9.5 Global Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.9.6 Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.10 Global Neuroendocrine Tumors (NETs) Market Segmentation: By End User
    • 3.10.1 Global Neuroendocrine Tumors (NETs) Market, By End User Overview
    • 3.10.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By End User Overview
    • 3.10.3 Global Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.10.4 Global Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics By Value, 2020H-2030F (USD Million & CAGR)
    • 3.10.5 Global Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)

4. Global Neuroendocrine Tumors (NETs) Market, Region Analysis

  • 4.1 Regional Coverage of the Study
  • 4.2 Regional Snapshot

5. Americas Neuroendocrine Tumors (NETs) Market: Historic and Forecast

  • 5.1 Americas Neuroendocrine Tumors (NETs) Market: Snapshot
  • 5.2 Americas Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 5.3 Americas Neuroendocrine Tumors (NETs) Market: Key Factors
  • 5.4 Americas Neuroendocrine Tumors (NETs) Market: Segment Analysis
  • 5.5 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
    • 5.5.1 Americas Neuroendocrine Tumors (NETs) Market, By Therapy Overview
    • 5.5.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
    • 5.5.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.5.4 Americas Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.6 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
    • 5.6.1 Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
    • 5.6.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.6.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.7 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
    • 5.7.1 Americas Neuroendocrine Tumors (NETs) Market, By Indication Overview
    • 5.7.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.7.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.7.4 Americas Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.7.5 Americas Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.8 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By End User
    • 5.8.1 Americas Neuroendocrine Tumors (NETs) Market, By End User Overview
    • 5.8.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.8.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.8.4 Americas Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.9 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Country
    • 5.9.1 Europe Neuroendocrine Tumors (NETs) Market, By Country Overview
    • 5.9.2 United States Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 5.9.2.1 United States Neuroendocrine Tumors (NETs) Market, By Therapy
      • 5.9.2.2 United States Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 5.9.2.3 United States Neuroendocrine Tumors (NETs) Market, By Indication
      • 5.9.2.4 United States Neuroendocrine Tumors (NETs) Market, By End User
    • 5.9.3 Canada Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 5.9.3.1 Canada Neuroendocrine Tumors (NETs) Market, By Therapy
      • 5.9.3.2 Canada Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 5.9.3.3 Canada Neuroendocrine Tumors (NETs) Market, By Indication
      • 5.9.3.4 Canada Neuroendocrine Tumors (NETs) Market, By End User
    • 5.9.4 Rest of Americas Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 5.9.4.1 Rest of Americas Neuroendocrine Tumors (NETs) Market, By Therapy
      • 5.9.4.2 Rest of Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 5.9.4.3 Rest of Americas Neuroendocrine Tumors (NETs) Market, By Indication
      • 5.9.4.4 Rest of Americas Neuroendocrine Tumors (NETs) Market, By End User

6. Europe Neuroendocrine Tumors (NETs) Market: Historic and Forecast

  • 6.1 Europe Neuroendocrine Tumors (NETs) Market: Snapshot
  • 6.2 Europe Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 6.3 Europe Neuroendocrine Tumors (NETs) Market: Key Factors
  • 6.4 Europe Neuroendocrine Tumors (NETs) Market: Segment Analysis
  • 6.5 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
    • 6.5.1 Europe Neuroendocrine Tumors (NETs) Market, By Therapy Overview
    • 6.5.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
    • 6.5.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.5.4 Europe Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.6 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
    • 6.6.1 Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
    • 6.6.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.6.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.7 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
    • 6.7.1 Europe Neuroendocrine Tumors (NETs) Market, By Indication Overview
    • 6.7.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.7.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.7.4 Europe Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.7.5 Europe Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.8 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By End User
    • 6.8.1 Europe Neuroendocrine Tumors (NETs) Market, By End User Overview
    • 6.8.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.8.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.8.4 Europe Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.9 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Country
    • 6.9.1 Europe Neuroendocrine Tumors (NETs) Market, By Country Overview
    • 6.9.2 United Kingdom Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.2.1 United Kingdom Neuroendocrine Tumors (NETs) Market, By Therapy
      • 6.9.2.2 United Kingdom Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 6.9.2.3 United Kingdom Neuroendocrine Tumors (NETs) Market, By Indication
      • 6.9.2.4 United Kingdom Neuroendocrine Tumors (NETs) Market, By End User
    • 6.9.3 Germany Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.3.1 Germany Neuroendocrine Tumors (NETs) Market, By Therapy
      • 6.9.3.2 Germany Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 6.9.3.3 Germany Neuroendocrine Tumors (NETs) Market, By Indication
      • 6.9.3.4 Germany Neuroendocrine Tumors (NETs) Market, By End User
    • 6.9.4 France Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.4.1 France Neuroendocrine Tumors (NETs) Market, By Therapy
      • 6.9.4.2 France Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 6.9.4.3 France Neuroendocrine Tumors (NETs) Market, By Indication
      • 6.9.4.4 France Neuroendocrine Tumors (NETs) Market, By End User
    • 6.9.5 Spain Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.5.1 Spain Neuroendocrine Tumors (NETs) Market, By Therapy
      • 6.9.5.2 Spain Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 6.9.5.3 Spain Neuroendocrine Tumors (NETs) Market, By Indication
      • 6.9.5.4 Spain Neuroendocrine Tumors (NETs) Market, By End User
    • 6.9.6 Rest of Europe Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.6.1 Rest of Europe Neuroendocrine Tumors (NETs) Market, By Therapy
      • 6.9.6.2 Rest of Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 6.9.6.3 Rest of Europe Neuroendocrine Tumors (NETs) Market, By Indication
      • 6.9.6.4 Rest of Europe Neuroendocrine Tumors (NETs) Market, By End User

7. Asia Pacific Neuroendocrine Tumors (NETs) Market: Historic and Forecast

  • 7.1 Asia Pacific Neuroendocrine Tumors (NETs) Market: Snapshot
  • 7.2 Asia Pacific Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 7.3 Asia Pacific Neuroendocrine Tumors (NETs) Market: Key Factors
  • 7.4 Asia Pacific Neuroendocrine Tumors (NETs) Market: Segment Analysis
  • 7.5 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
    • 7.5.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Therapy Overview
    • 7.5.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
    • 7.5.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.5.4 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.6 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
    • 7.6.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
    • 7.6.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.6.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.7 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
    • 7.7.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Indication Overview
    • 7.7.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.7.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.7.4 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.7.5 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.8 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By End User
    • 7.8.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By End User Overview
    • 7.8.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.8.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.8.4 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.9 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Country
    • 7.9.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Country Overview
    • 7.9.2 China Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.2.1 China Neuroendocrine Tumors (NETs) Market, By Therapy
      • 7.9.2.2 China Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 7.9.2.3 China Neuroendocrine Tumors (NETs) Market, By Indication
      • 7.9.2.4 China Neuroendocrine Tumors (NETs) Market, By End User
    • 7.9.3 Japan Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.3.1 Japan Neuroendocrine Tumors (NETs) Market, By Therapy
      • 7.9.3.2 Japan Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 7.9.3.3 Japan Neuroendocrine Tumors (NETs) Market, By Indication
      • 7.9.3.4 Japan Neuroendocrine Tumors (NETs) Market, By End User
    • 7.9.4 India Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.4.1 India Neuroendocrine Tumors (NETs) Market, By Therapy
      • 7.9.4.2 India Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 7.9.4.3 India Neuroendocrine Tumors (NETs) Market, By Indication
      • 7.9.4.4 India Neuroendocrine Tumors (NETs) Market, By End User
    • 7.9.5 South Korea Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.5.1 South Korea Neuroendocrine Tumors (NETs) Market, By Therapy
      • 7.9.5.2 South Korea Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 7.9.5.3 South Korea Neuroendocrine Tumors (NETs) Market, By Indication
      • 7.9.5.4 South Korea Neuroendocrine Tumors (NETs) Market, By End User
    • 7.9.6 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.6.1 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By Therapy
      • 7.9.6.2 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 7.9.6.3 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By Indication
      • 7.9.6.4 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By End User

8. Middle East and Africa Neuroendocrine Tumors (NETs) Market: Historic and Forecast

  • 8.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Snapshot
  • 8.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 8.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Key Factors
  • 8.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Segment Analysis
  • 8.5 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
    • 8.5.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Therapy Overview
    • 8.5.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
    • 8.5.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.5.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.6 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
    • 8.6.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
    • 8.6.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.6.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.7 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
    • 8.7.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Indication Overview
    • 8.7.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.7.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.7.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.7.5 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.8 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By End User
    • 8.8.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By End User Overview
    • 8.8.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.8.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.8.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)

9. Market Dynamics

  • 9.1 Impact assessment of Market Dynamics on Global Neuroendocrine Tumors (NETs) Market
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Trends

10. Industry Ecosystem Analysis

  • 10.1 Porter Analysis

11. Competitive Positioning

  • 11.1 Companies' Product Positioning
  • 11.2 Market Share of Leading Companies
  • 11.3 Company Profiling
    • 11.3.1 Novartis
    • 11.3.2 Pfizer
    • 11.3.3 Amgen, Inc.
    • 11.3.4 GlaxoSmithKline
    • 11.3.5 F. Hoffmann-La Roche AG
    • 11.3.6 Bristol-Myers Squibb Co.
    • 11.3.7 Eli Lilly and Company
    • 11.3.8 Ipsen
    • 11.3.9 Lantheus Holdings
    • 11.3.10 Boehringer Ingelheim

12. About Us and Disclaimer

List of Figures

  • Figure 1: Global Neuroendocrine Tumors (NETs) Market Size, By Value, 2020-2023 (USD Million)
  • Figure 2: Global Neuroendocrine Tumors (NETs) Market Size, By Value, 2024-2030 (USD Million)
  • Figure 3: Global Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
  • Figure 4: Market Attractiveness Analysis of Global Neuroendocrine Tumors (NETs) Market, By Therapy (2025-2030)
  • Figure 5: Global Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 6: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Somatostatin Analogs (SSAs), 2020H-2030F (USD Million)
  • Figure 7: Global Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 8: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Targeted Therapy, 2020H-2030F (USD Million)
  • Figure 9: Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 10: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Others, 2020H-2030F (USD Million)
  • Figure 11: Market Attractiveness Analysis of Global Neuroendocrine Tumors (NETs) Market, By Route of Administration (2025-2030)
  • Figure 12: Global Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 13: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Oral, 2020H-2030F (USD Million)
  • Figure 14: Global Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 15: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Parenteral, 2020H-2030F (USD Million)
  • Figure 16: Market Attractiveness Analysis of Global Neuroendocrine Tumors (NETs) Market, By Indication (2025-2030)
  • Figure 17: Global Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 18: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Lung Endocrine Tumor, 2020H-2030F (USD Million)
  • Figure 19: Global Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 20: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Pancreatic Endocrine Tumor, 2020H-2030F (USD Million)
  • Figure 21: Global Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 22: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Gastrointestinal Endocrine Tumor, 2020H-2030F (USD Million)
  • Figure 23: Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 24: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Others, 2020H-2030F (USD Million)
  • Figure 25: Market Attractiveness Analysis of Global Neuroendocrine Tumors (NETs) Market, By End User (2025-2030)
  • Figure 26: Global Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 27: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Hospitals, 2020H-2030F (USD Million)
  • Figure 28: Global Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 29: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Specialty Clinics, 2020H-2030F (USD Million)
  • Figure 30: Global Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 31: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Radiation Centers, 2020H-2030F (USD Million)
  • Figure 32: Americas Neuroendocrine Tumors (NETs) Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 33: Americas Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
  • Figure 34: Americas Neuroendocrine Tumors (NETs) Market, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 35: Americas Neuroendocrine Tumors (NETs) Market, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 36: Americas Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 37: Americas Neuroendocrine Tumors (NETs) Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 38: Americas Neuroendocrine Tumors (NETs) Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 39: Americas Neuroendocrine Tumors (NETs) Market, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 40: Americas Neuroendocrine Tumors (NETs) Market, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 41: Americas Neuroendocrine Tumors (NETs) Market, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 42: Americas Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 43: Americas Neuroendocrine Tumors (NETs) Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 44: Americas Neuroendocrine Tumors (NETs) Market, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 45: Americas Neuroendocrine Tumors (NETs) Market, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 46: United States Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 47: United States Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 48: United States Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 49: United States Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 50: United States Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 51: United States Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 52: Canada Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 53: Canada Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 54: Canada Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 55: Canada Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 56: Canada Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 57: Canada Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 58: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 59: Rest of Americas Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 60: Rest of Americas Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 61: Rest of Americas Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 62: Rest of Americas Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 63: Rest of Americas Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 64: Europe Neuroendocrine Tumors (NETs) Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 65: Europe Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
  • Figure 66: Europe Neuroendocrine Tumors (NETs) Market, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 67: Europe Neuroendocrine Tumors (NETs) Market, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 68: Europe Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 69: Europe Neuroendocrine Tumors (NETs) Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 70: Europe Neuroendocrine Tumors (NETs) Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 71: Europe Neuroendocrine Tumors (NETs) Market, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 72: Europe Neuroendocrine Tumors (NETs) Market, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 73: Europe Neuroendocrine Tumors (NETs) Market, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 74: Europe Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 75: Europe Neuroendocrine Tumors (NETs) Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 76: Europe Neuroendocrine Tumors (NETs) Market, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 77: Europe Neuroendocrine Tumors (NETs) Market, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 78: United Kingdom Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 79: United Kingdom Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 80: United Kingdom Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 81: United Kingdom Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 82: United Kingdom Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 83: United Kingdom Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 84: Germany Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 85: Germany Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 86: Germany Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 87: Germany Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 88: Germany Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 89: Germany Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 90: France Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 91: France Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 92: France Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 93: France Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 94: France Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 95: France Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 96: Spain Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 97: Spain Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 98: Spain Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 99: Spain Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 100: Spain Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 101: Spain Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 102: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 103: Rest of Europe Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 104: Rest of Europe Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 105: Rest of Europe Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 106: Rest of Europe Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 107: Rest of Europe Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 108: Asia-Pacific Neuroendocrine Tumors (NETs) Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 109: Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
  • Figure 110: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 111: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 112: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 113: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 114: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 115: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 116: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 117: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 118: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 119: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 120: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 121: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 122: China Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 123: China Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 124: China Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 125: China Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 126: China Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 127: China Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 128: Japan Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 129: Japan Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 130: Japan Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 131: Japan Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 132: Japan Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 133: Japan Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 134: India Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 135: India Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 136: India Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 137: India Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 138: India Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 139: India Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 140: South Korea Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 141: South Korea Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 142: South Korea Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 143: South Korea Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 144: South Korea Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 145: South Korea Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 146: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 147: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 148: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 149: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 150: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 151: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 152: Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 153: Middle East and Africa Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
  • Figure 154: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 155: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 156: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 157: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 158: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 159: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 160: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 161: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 162: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 163: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 164: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 165: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 166: Global Impact of Drivers and Restraints
  • Figure 167: Market Share of Prominent Companies of Neuroendocrine Tumors (NETs), 2023 (%)
  • Figure 168: Novartis Revenues, 2021-2023 (USD Billion)
  • Figure 169: Novartis Revenue , By Business Segments, 2023 (%)
  • Figure 170: Novartis Revenue , By Geographical Segments, 2023 (%)
  • Figure 171: Pfizer Revenues, 2021-2023 (USD Billion)
  • Figure 172: Pfizer Revenues, By Business Segments, 2023 (%)
  • Figure 173: Pfizer Inc. Revenue , By Geographical Segments, 2023 (%)
  • Figure 174: Amgen, Inc. Revenues, 2021-2023 (USD Million)
  • Figure 175: Amgen, Inc. Revenues, By Geographic Segments, 2023 (%)
  • Figure 176: Amgen, Inc. Revenue , By Products, 2023 (%)
  • Figure 177: GSK Revenue, 2021-2023 (USD Billion)
  • Figure 178: GSK Revenue , By Business Segments, 2023 (%)
  • Figure 179: GSK Revenue, By Geographical Segment, 2023 (%)
  • Figure 180: Roche Revenues, 2021-2023 (USD Billion)
  • Figure 181: Roche Revenue , By Business Segment, 2023 (%)
  • Figure 182: Bristol-Myers Squibb Revenues, 2021-2023 (USD Billion)
  • Figure 183: Bristol-Myers Squibb Revenues, By Geographic Segments, 2023 (%)
  • Figure 184: Eli Lilly and Company Revenues, 2021-2023 (USD Billion)
  • Figure 185: Eli Lilly and Company Revenues, By Geographic Segments, 2023 (%)
  • Figure 186: Eli Lilly and Company Revenue , By Business Segments, 2023 (%)
  • Figure 187: Ipsen Revenues, 2021-2023 (USD Million)
  • Figure 188: Ipsen Revenue, By Business Segments, 2023 (%)
  • Figure 189: Ipsen Revenue, By Geographical Segments, 2023 (%)
  • Figure 190: Lantheus Revenues, 2021-2023 (USD Million)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region

Table A2: Neuroendocrine Tumor (NETs) Therapies in Pipeline

Table A3: United States Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A4: United States Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A5: United States Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A6: United States Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A7: United States Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A8: United States Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A9: United States Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A10: United States Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A11: Canada Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A12: Canada Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A13: Canada Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A14: Canada Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A15: Canada Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A16: Canada Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A17: Canada Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A18: Canada Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A19: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A20: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A21: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A22: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A23: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A24: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A25: Rest of Americas Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A26: Rest of Americas Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A27: United Kingdom Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A28: United Kingdom Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A29: United Kingdom Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A30: United Kingdom Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A31: United Kingdom Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A32: United Kingdom Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A33: United Kingdom Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A34: United Kingdom Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A35: Germany Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A36: Germany Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A37: Germany Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A38: Germany Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A39: Germany Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A40: Germany Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A41: Germany Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A42: Germany Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A43: France Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A44: France Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A45: France Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A46: France Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A47: France Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A48: France Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A49: France Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A50: France Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A51: Spain Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A52: Spain Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A53: Spain Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A54: Spain Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A55: Spain Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A56: Spain Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A57: Spain Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A58: Spain Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A59: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A60: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A61: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A62: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A63: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A64: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A65: Rest of Europe Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A66: Rest of Europe Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A67: China Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A68: China Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A69: China Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A70: China Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A71: China Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A72: China Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A73: China Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A74: China Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A75: Japan Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A76: Japan Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A77: Japan Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A78: Japan Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A79: Japan Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A80: Japan Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A81: Japan Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A82: Japan Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A83: India Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A84: India Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A85: India Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A86: India Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A87: India Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A88: India Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A89: India Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A90: India Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A91: South Korea Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A92: South Korea Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A93: South Korea Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A94: South Korea Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A95: South Korea Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A96: South Korea Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A97: South Korea Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A98: South Korea Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A99: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A100: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A101: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A102: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A103: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A104: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A105: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A106: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A107: Novartis Key Company Financials, 2021-2023

Table A108: Pfizer Key Financials, 2021-2023

Table A109: Amgen, Inc. Key Financials, 2021-2023

Table A110: GSK Key Company Financials, 2021-2023

Table A111: Roche Key Financials, 2021-2023

Table A112: Bristol-Myers Squibb Key Financials, 2021-2023

Table A113: Eli Lilly and Company Key Financials, 2021-2023

Table A114: Ipsen Key Company Financials, 2021-2023

Table A115: Lantheus Key Company Financials, 2021-2023